The U.S. Embassy welcomed the arrival of an additional 1.5 million doses of Pfizer?vaccine?to Cairo on December 25.? Chargé d’Affaires, a.i. Nicole Shampaine noted, “This delivery of another 1.5 million Pfizer vaccine doses to Egypt through COVAX means the United States has now donated 15 million doses of Coronavirus?vaccines?to the people of Egypt to help protect Egyptians from the virus and prevent the spread of its dangerous new strains.??The emergence of the Omicron variant places even greater importance on our working together, as strategic partners, to overcome the pandemic.”??
The Pfizer doses will be dispatched to Ministry of Health and Population facilities in Cairo and stored in UNICEF-funded ultra-cold storage equipment used exclusively for the Pfizer?vaccine. The vaccines will be distributed across the country for administration to Egyptian citizens and?residents.?
U.S. cooperation with Egypt in fighting the pandemic is wide-ranging. The U.S. government, through USAID, has provided more than $55 million to support Egypt’s Coronavirus?response, reaching nearly 18 million people. USAID programs train health care workers, help deliver vaccines to the Egyptian people, improve tracking of and?response to the pandemic, and support small businesses. This support builds on the more than $1 billion the United States has invested in Egypt over the past 40 years to improve the health of all Egyptians.?
Distributed by APO Group on behalf of U.S. Embassy - Cairo, Egypt.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
